Johnson & Johnson (J&J; New Brunswick, New Jersey) and its DePuy (Warsaw, Indiana) orthopedics division are both coming under fire after an article in The New York Times reported that the firm continued to market its articular surface replacement (ASR) hip implant overseas after the FDA rejected the sale of the device in the U.S.